Botulinum Toxin Market Size, Share & Industry Analysis, By Application (Therapeutic {Chronic Migraine, Spasticity, Overactive Bladder, Cervical Dystonia, Blepharospasm, and Others} and Aesthetics), By Type (Botulinum Toxin Type A and Botulinum Toxin Type B), By End-user (Specialty & Dermatology Clinics, Hospitals & Clinics, and Others), and Regional Forecast, 2024-2032

The global botulinum toxin market size was valued at USD 8.14 billion in 2023 and is projected to grow from USD 8.74 billion in 2024 to USD 16.01 billion by 2032, exhibiting a CAGR of 7.9% during the forecast period (2024-2032).

The botulinum toxin, a neurotoxin, is produced by a gram-positive anaerobic bacterium named clostridium botulinum. This toxin can be divided into seven different neurotoxins with distinct antigenic and serological characteristics but similar structures. Currently, the market offers Type A and Type B forms of the toxin, which are used in various therapeutic and aesthetic procedures.

In recent years, there has been an increasing demand for these non-invasive cosmetic procedures, primarily driven by advanced product launches, rising disposable incomes, and favorable reimbursement policies. Market players in the global market are also focused on developing innovative products to expand their portfolios and improve patient outcomes in therapeutic and aesthetic settings.

• For instance, AbbVie Inc. announced positive results from a Phase 3 clinical study in September 2023, evaluating the use of onabotulinumtoxinA (BOTOX Cosmetic) for the treatment of moderate to severe platysma prominence associated with platysma muscle activity (M21-310). This showcases the ongoing efforts to meet the demand for aesthetic beauty globally. Furthermore, initiatives by market players to raise awareness about these products drive market growth.

The COVID-19 pandemic had a negative impact on the global market, leading to a decline in cosmetic procedures in 2020. Prominent market players experienced reduced revenue from neurotoxin preparations during the 2020 financial year. However, the market began recovering in 2021 as dermatology clinics reopened and people resumed seeking these procedures. The increased adoption of advanced product offerings and a rise in patient visits have helped the global market regain its pre-pandemic growth levels in 2022. The market is expected to sustain stable growth between 2024 and 2032.

Botulinum Toxin Market Trends

Dissemination of Awareness through Various Promotional Activities by Major Players to Enhance Product Adoption

The leading players in the market are implementing new and improved marketing plans to increase the global awareness of these products among consumers. Significant players, such as Abbvie Inc. and Merz Pharma, are implementing marketing plans to increase customer awareness.

• For instance, in September 2023, AbbVie Inc. announced the next chapter of the BOTOX Cosmetic and IFundWomen grant program by launching crowdfunding campaigns for women entrepreneurs. The brand recently announced the recipients, each receiving a USD 25,000 grant from the company and coaching and mentorship. The crowdfunding campaigns at ifundwomen.com/BOTOXCosmetic spotlight the entrepreneurs and encourage consumers to support their businesses to continue empowering women leaders of tomorrow.

Market players' use of social media platforms, such as Instagram and Facebook, has also become an essential marketing tool. Many cosmetic surgeons say that patients around the world have been asking them to perform procedures that make them look better, such as software-filtered versions of themselves. Therefore, major brands are taking steps to engage with consumers by casting celebrities to promote their products and launching campaigns that address people's concerns. This will contribute to the growth of the market in the coming years.

Botulinum Toxin Market Growth Factors

Robust Demand of Non-Invasive Procedures to Augment Market Expansion

The demand for minimally invasive and non-invasive procedures has increased in recent years. In fact, according to the ISAPS 2022 report, an estimated 18,857,311 nonsurgical procedures were performed worldwide in 2021. Hyaluronic acid, botulinum toxin procedures, and laser hair removal accounted for 7.2% of the total nonsurgical procedures.

Furthermore, as per ISAPS, the total number of botulinum toxin procedures in 2022 was 9,221, 419. The increase in procedures is due to a sudden rise in the number of people seeking simple and painless ways to look young and healthy without having to deal with the issues that come with invasive cosmetic procedures. The increase in demand has also caused manufacturers and suppliers of non-invasive cosmetic technology to concentrate on these products. Major players have started to focus on launching advanced products into the market by either filing for regulatory approval or concentrating on research and development activities.

• For instance, in October 2023, GALDERMA updated related to the regulatory progress of its pending Biologics License Application (BLA) for RelabotulinumtoxinA (QM-1114) to the U.S. Food and Drug Administration (FDA).

Significant Rise in R&D Initiatives for Expansion of Aesthetic and Applications to Propel Market Growth

The products can be used for both therapeutic and aesthetic purposes. Due to the dual use of the product, there is an increase in the demand for these products among the general public. The rise in critical and chronic diseases, such as spasticity, cervical dystonia, and chronic migraine, also drives market growth.

• For instance, according to an article published by the National Institutes of Health (NIH) in 2023, a retrospective study enrolled adult patients with a history of intracerebral hemorrhage (ICH) between January 2012 and October 2020. The incidence of spasticity in patients with brainstem hemorrhage was the highest, about 36.8%, among all the lesion locations.

The expansion of the global market was also driven by the expansion of major pharmaceutical companies' R&D efforts to offer treatment options for these critical diseases. In addition to therapeutic applications, they also have regulatory approvals for aesthetic indications, such as forehead lines, crow's feet, and frown lines. The clinical trials by prominent companies to extend the aesthetic use of existing products drive global botulinum toxin market growth. For instance, in July 2022, Abbvie Inc. conducted a study on BOTOX injections to assess the changes in disease symptomatology in patients suffering from upper limb essential tremors.

RESTRAINING FACTORS

Growing Presence and Access to Counterfeit Products Hinder Market Growth

These products have established a significant position in the global market due to their applications in cosmetic and therapeutic procedures. They also offer other therapeutic benefits for children with cerebral palsy or adults suffering from stroke. In addition to therapeutics, neurotoxin is also being used increasingly in cosmetics. However, as the demand for these products increases, so does the number of counterfeit products available to meet that demand. The generalization of branded products has caused counterfeit products to enter the market. Many beauticians and online customers are using illegal products, which have caused harm to many people.

These counterfeit products mimic authentic brands in terms of packaging and trademarks, misleading customers with their lower prices. However, these products are produced illegally and are unregulated, posing risks and side effects to consumers. The U.S. FDA has issued warnings in response to this issue, and regulatory bodies worldwide have seized counterfeit shipments.

• For instance, the World Health Organization (WHO) issued an alert in August 2022 regarding falsified versions of Ipsen's Dysport being discovered in multiple countries.

The increasing availability of these cheaper fake products may hinder the growth of genuine ones as consumers opt for affordability, impacting the revenue of major companies.

Botulinum Toxin Market Segmentation Analysis

By Application Analysis

Multiple Product Launches in Therapeutics Drive Therapeutics Segment Growth

Based on application, the market is segmented into aesthetics and therapeutics. The therapeutics segment is further sub-segmented into blepharospasm, chronic migraine, overactive bladder, spasticity, cervical dystonia, and others.

The therapeutics segment held a dominant botulinum toxin market share in 2023. There is a rise in investments in R&D initiatives to launch products and focus on getting regulatory approvals for treating diverse diseases by key market players.

For instance, AbbVie Inc. showcased its collection of migraine treatments and research findings at the 16th European Headache Federation Congress 2022 (EHC 2022) held in December 2022. The presentation encompassed 15 abstracts that examined various studies, such as the data on onabotulinumtoxinA and atogepant. As a result, the expanding therapeutic uses of botulinum toxin are predicted to significantly enhance the market's growth prospects from 2024 to 2032.

By therapeutics, spasticity has the highest global market share due to the increasing prevalence of related diseases, such as multiple sclerosis. Chronic migraine is the second highest sub-segment due to the high prevalence of this disease across the globe. Moreover, as per the article published in 2023 by Wolters Kluwer in 2023, 5 to 30 cases per 100,000 individuals is the estimated prevalence of cervical dystonia ranges. In the U.S., the estimated incidence is 1.18 per 100,000 person-years. The segment is expected to show steady growth prospects in 2024-2032.

On the other hand, the aesthetics segment accounted for a considerable share in 2023. The demand for botulinum toxin is likely to be driven by the growing need for minimally invasive treatments and the increasing awareness of using these products for cosmetic purposes. For instance, according to ISAPS, in 2022, 9,221,419 cosmetic minimally-invasive botulin toxin procedures were performed worldwide. A rising number of procedures contributed to expanding the segment’s growth.

By Type Analysis

Large Number of Product Approvals to Drive Botulinum Toxin Type A Segment Growth

On the basis of type, the market is segmented into botulinum toxin type A and botulinum toxin type B. In 2023, the botulinum toxin type A segment accounted for the largest global botulinum toxin market share. The segment is projected to have the highest CAGR in the coming years. The segment’s dominance can be attributed to the large number of product introductions. Major players’ ongoing efforts to launch new, promising clinical trial results and innovative type A products also play a positive role in segmental growth.

• For instance, in August 2023, AbbVie Inc. announced that the Journal of Cosmetic Dermatology published results from a year-long, post-hoc analysis of patient-reported outcomes (PROs) from two Phase 3 clinical studies evaluating the impact of onabotulinumtoxinA (BOTOX Cosmetic) on upper facial lines (UFLs) in adults new to toxin treatment. The peer-reviewed study stated that 90.5% of all study patients with 30 days of treatment reported being either mostly or very satisfied with receiving a natural look, as rated on a five-point scale. In addition, type A injection remains the most commonly performed cosmetic procedure worldwide. Surveys conducted by leading specialist organizations consistently rank type A injection at the top of the list of nonsurgical methods reported by members.

The botulinum toxin type B segment is expected to grow at a slower pace in the forecast period due to fewer product launches and fewer clinical trials being performed on these products. Key stakeholders will continue to focus on expanding the therapeutic uses of Myobloc after the strategic acquisition of Supernus Pharmaceuticals, Inc. from the U.S. Worldmeds LLC (USWM, LLC), which will contribute to the segment’s growth.

By End-user Analysis

Strong Preference for Specialty & Dermatology Clinics Drives Segment Growth

In terms of end-user, the market is segmented into specialty & dermatology clinics, hospitals & clinics, and others.

The specialty & dermatology clinics segment accounted for the largest market share. A significant percentage of procedures are performed in these clinics compared to hospitals. This is one of the main reasons for the segment's growth. The increasing number of aesthetic issues, such as frown lines, Glabellar Lines, and Crow’s Feet, are expected to contribute to the development of this segment.

The hospitals & clinics segment held the second-largest share in 2023. This segment is driven by the high volume of aesthetic and therapeutic procedures performed in hospitals & clinics. For instance, according to ISAPS, 47.4 % of total cosmetic procedures were performed in hospitals in 2022. The others segment is projected to grow slower as skilled professionals are less likely to work in these settings.

REGIONAL INSIGHTS

On the basis of region, the global market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America has the largest market share and generated a revenue of USD 5.40 billion in 2023. This is due to the growing number of product launches in the region, the presence of large companies, and the increasing acceptance of these procedures among the people in the region. For instance, according to the ISAPS, around 3,945,282 Botulinum toxin procedures occurred in the U.S. in 2022. The growth of product launches is also due to the increasing regulatory approvals of these products for therapeutic applications.

Europe had the second largest market share due to the increasing number of people opting for these procedures in key European markets. Additionally, the growing spending on research and development to introduce new products is one of the critical reasons for the European region's growth. For instance, according to ISAPS, in 2022, 210,355 nonsurgical cosmetic operations were carried out in Spain, 74,826 of which were botulinum toxin procedures.

Asia Pacific is projected to grow at a faster CAGR than the rest of the world. These procedures are becoming more popular in Asia due to the rise in chronic diseases and the growing awareness of physical appearance. The majority of these procedures are performed in specialist and dermatological clinics. Furthermore, increasing research efforts to improve patient outcomes also drives market growth.

• As per an article published in 2022 by the Multidisciplinary Digital Publishing Institute (MDPI), a survey was conducted to determine the cosmetic practice pattern of type A botulinum toxin injection. In this survey, an 18-item questionnaire was distributed to dermatologists. The survey was conducted to make clinicians better understand patients' needs and optimize cosmetic procedures with these products.

The growing procedures volume in major Latin American countries, such as Brazil, will drive the market's growth. The increasing adoption of these products for cosmetic procedures in this region and the growing awareness among people will also drive the development of this market. For instance, according to the ISAPS, in Brazil, in 2022, 44.6% of all nonsurgical cosmetic injectable procedures were performed with these products.

In the Middle East & Africa, the number of cosmetic injectable procedures is expected to continue to grow. The increasing per capita healthcare spending and rising health and beauty norms have driven the market’s growth.

Key Industry Players in Botulinum Toxin Market

Robust Product Offerings and Global Reach to Enable AbbVie Inc. and Ipsen Pharma to Reach Market Dominance

There are a variety of players in the global botulinum toxin market, ranging from big players to small and growing regional players. The dominant player in the global market is Abbvie Inc., which holds a significant market share due to its strong product portfolio, which includes BOTOX Cosmetic and BOTOX Therapeutic. The wide range of applications of the company's product portfolio and the company's consistent efforts to participate in clinical trials contribute to the company's growth.

• For instance, in October 2023, AbbVie Inc. announced positive topline results from two pivotal Phase 3 clinical studies evaluating trenibotulinumtoxinE (BoNT/E). It treats moderate to severe glabellar lines (M21-500 and M21-508).

Ipsen Pharma, Merz Pharma, and Medytox are working on strategic initiatives, including new product launches and getting regulatory approvals to market their products globally. For instance, Ipsen Pharma reported in June 2022 that Dysport received a favorable opinion in Europe for the treatment of urinary incontinence among adults with neurogenic dermoid overactivity (which can be caused by spinal cord injury or multiple sclerosis). Other players, such as Medytox, GALDERMA, and HUGEL, Inc., aim to gain a significant market share over the next few years. The rise in investments in the global market is one of the major strategic moves by these companies. For instance, Hugel Inc. aims to launch its products in several European countries. GALDERMA aims to get regulatory approvals for Dysport in China as a glabellar line treatment. These companies' initiatives will help them maintain their presence in the global market.

LIST OF TOP BOTULINUM TOXIN COMPANIES:

• AbbVie Inc. (U.S.)


• Ipsen Pharma (France)


• Merz Pharma (Germany)


• Medytox (South Korea)


• GALDERMA (Switzerland)


• Lanzhou Institute of Biological Products Co., Ltd. (China)


• HUGEL, Inc. (South Korea)


• Evolus, Inc. (U.S.)


• Revance Therapeutics, Inc. (U.S.)


• Supernus Pharmaceuticals, Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• November 2023: AbbVie’s New and loyal members of Allē, the Allergan Aesthetics loyalty program, provide an opportunity to buy, earn, and win with this year's BOTOX Cosmetic Day offers.


• December 2022: Gufic Biosciences collaborated with the U.S.-based Prime Bio to launch botulinum toxin type A injection, ‘Zarbot’, in India.


• October 2022: Evolus, Inc. commercially launched its operations in Great Britain and shipped the first customer orders for Nuceiva (type A). This development contributes toward the company’s aim for global expansion.


• October 2022: Galderma continued collaborating with the National Breast Cancer Foundation Inc. (NBCF). In a social media campaign across Galderma’s social channels, NBCF shared the stories and experiences of breast cancer patients who were treated with the company’s products, such as Restylane and Dysport (ABOOTULANTA (toxin A)) or Sculptra in Breast Cancer Awareness month.


• August 2022: ATGC Co., Ltd. signed a strategic partnership, license, and supply agreement with RELIFE S.r.l (Menarini Group) for ATGC-100 (Botulinum Toxin Type A, 900kDa) as part of its strategic entry into Europe and the U.K.


• August 2022: Medytox and Bloomage Biotechnology announce the termination of their partnership. According to a statement provided by Bloomage Biotechnology, Medytox has not sold Medybloom China BTX products since the signing of the joint venture agreement.


• April 2022: Medytox subsidiary Medytox Korea has completed the Phase III clinical trial for their next-generation (BTX) MBA-P01. Such developments contribute to easy marketing approval of the product.

REPORT COVERAGE

The global market report provides an in-depth analysis of the market, including the number of procedures per key country, the types of botulinum toxin products, pipeline analysis, regulatory and reimbursement scenario, new product launches/approvals, application of these products in therapeutics, and key industry trends. The market report also provides insights into market trends, COVID-19's impact on the global market, and several factors that contributed to the growth of the market in the study period of 2019-2032.

Report Scope & Segmentation

ATTRIBUTE	DETAILS
Study Period	2019-2032
Base Year	2023
Estimated Year	2024
Forecast Period	2024-2032
Historical Period	2019-2022
Growth Rate	CAGR of 7.9% from 2024-2032
Unit	Value (USD Billion)
Segmentation	By Application Therapeutics Chronic Migraine Spasticity Overactive Bladder Cervical Dystonia Blepharospasm Others Aesthetics
By Type Botulinum Toxin Type A Botulinum Toxin Type B
By End-user Specialty & Dermatology Clinics Hospitals & Clinics Others
By Region North America (By Application, Type, End-user, and Country) U.S. (By Application) Canada (By Application) Europe (By Application, Type, End-user, and Country/Sub-Region) U.K. (By Application) Germany (By Application) France (By Application) Italy (By Application) Spain (By Application) Scandinavia (By Application) Rest of Europe (By Application) Asia Pacific (By Application, Type, End-user, and  Country/Sub-Region) Japan (By Application) China (By Application) India (By Application) Australia (By Application) South Korea (By Application) Southeast Asia (By Application) Rest of Asia Pacific (By Application) Latin America (By Application, Type, End-user, and Country/Sub-Region) Brazil (By Application) Mexico (By Application) Rest of Latin America (By Application) Middle East & Africa (By Application, Type, End-user, and Country/Sub-Region) GCC (By Application) South Africa (By Application) Rest of Middle East & Africa (By Application)